Annotation Detail
Information
- Associated Genes
- CCND1
- Associated Variants
-
CCND1 AMPLIFICATION
(
ENST00000227507.3 )
CCND1 AMPLIFICATION ( ENST00000227507.3 ) - Associated Disease
- skin melanoma
- Source Database
- CIViC Evidence
- Description
- Retrospective analysis of somatic mutations and copy number changes in 119 patient treated with carboplatin, paclitaxel, ± sorafenib (CPS) in the E2603 trial. CPS therapy was associated with improved progression-free survival (PFS) compared with CP in patients with tumors with CCND1 gene copy gains (HR, 0.45; P = 0.035).
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1495
- Gene URL
- https://civic.genome.wustl.edu/links/genes/8
- Variant URL
- https://civic.genome.wustl.edu/links/variants/18
- Rating
- 2
- Evidence Type
- Predictive
- Disease
- Skin Melanoma
- Evidence Direction
- Supports
- Drug
- Paclitaxel,Carboplatin,Sorafenib
- Evidence Level
- B
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 26307133
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Carboplatin | Sensitivity | true |
| Paclitaxel | Sensitivity | true |
| Sorafenib | Sensitivity | true |